Lowering blood sugar effect crushes competitors! Eli Lilly's (LLY.US) oral weight loss drug achieves success in Phase III clinical trials, planning to apply for market approval next year.

Eli Lilly (LLY.US) announced on Wednesday that its oral weight-loss candidate drug orforglipron has achieved primary endpoints in two Phase III clinical trials for patients with type 2 diabetes, demonstrating the potential of the drug in controlling blood sugar levels. The Indiana-based pharmaceutical company stated that based on the results of the ACHIEVE-2 and ACHIEVE-5 trials, the once-daily GLP-1 receptor agonist orforglipron has the potential to become a new standard in the treatment of type 2 diabetes. According to preliminary results, the ACHIEVE-2 trial met its primary endpoint. Compared to a reduction of 0.8% with Astrazeneca PLC's sponsored ADR drug Farxiga, orforglipron achieved the highest reduction in the levels of the diabetes biomarker glycosylated hemoglobin (A1C) at 1.7%. The ACHIEVE-5 trial also met its primary endpoint. When used in combination with basal insulin, orforglipron resulted in an additional 2.1% reduction in A1C levels. ACHIEVE-2 included adult patients with type 2 diabetes who had inadequate blood sugar control after treatment with metformin, while ACHIEVE-5 focused on similar patients with inadequate control on basal insulin. Both 40-week studies tested three doses of 3mg, 12mg, and 36mg. Eli Lilly added that both trials collected safety and tolerability data, and the treatment discontinuation rates were consistent with data from previous trials of the drug. The final global registration trial of Eli Lilly's ACHIEVE project is expected to announce results in the first quarter of 2026, with plans to seek global regulatory approval for orforglipron for type 2 diabetes indications next year. Additionally, Eli Lilly reiterated its plan to submit approval data for the use of the drug in the treatment of obesity by the end of 2025.